Nov 8 (Reuters) - Allovir Inc ( ALVR ):
* ALLOVIR AND KALARIS THERAPEUTICS ANNOUNCE AGREEMENT FOR
TRANSFORMATIONAL MERGER TO CREATE COMPANY FOCUSED ON DISEASES OF
THE RETINA
* ALLOVIR INC ( ALVR ) - TO ACQUIRE 100% OF KALARIS EQUITY INTEREST
* ALLOVIR INC ( ALVR ) - STOCKHOLDERS TO OWN 25.05% OF COMBINED
COMPANY
POST-MERGER
* ALLOVIR INC ( ALVR ) - COMBINED COMPANY TO BE LED BY KALARIS CEO
ANDREW
OXTOBY
* ALLOVIR INC ( ALVR ) - COMBINED COMPANY TO OPERATE AS KALARIS
THERAPEUTICS, INC. AND TRADE AS KLRS
* ALLOVIR INC ( ALVR ) - TH103 PHASE 1 CLINICAL TRIAL DATA EXPECTED
IN Q3
2025
Source text:
Further company coverage: